{"nctId":"NCT03679884","briefTitle":"Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep","startDateStruct":{"date":"2018-10-09","type":"ACTUAL"},"conditions":["Insomnia Disorder"],"count":804,"armGroups":[{"label":"Daridorexant 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Daridorexant 10 mg"]},{"label":"Daridorexant 25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Daridorexant 25 mg"]},{"label":"Daridorexant 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Daridorexant 50 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ex-Placebo Daridorexant 25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Daridorexant 25 mg"]}],"interventions":[{"name":"Daridorexant 10 mg","otherNames":[]},{"name":"Daridorexant 25 mg","otherNames":[]},{"name":"Daridorexant 50 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent prior to any study-mandated procedure (Visit 1).\n* Having completed the DB study treatment and the run-out period of ID-078A301 (NCT03545191) or ID-078A302 (NCT03575104).\n* For woman of childbearing potential, the following is required:\n\n  * Negative urine pregnancy test (EOT of ID-078A301 or ID-078A302 studies)\n  * Agreement to use the contraception scheme as required by the protocol from Visit 1 up to at least 30 days after EODBT.\n\nExclusion Criteria:\n\n* Unstable medical condition, significant medical disorder or acute illness, C-SSRSÂ©, ECG, hematology or biochemistry test results in ID-078A301 and ID-078A302, which in the opinion of the investigator could affect the subject's safety or interfere with the study assessments (Visit 1).\n* For female subjects: lactating or planning to become pregnant during the duration of the study (Visit 1).\n* Positive urine drug test (for benzodiazepines, barbiturates, cannabinoids, opiates, amphetamines, or cocaine) or presence of alcohol in exhaled breath as detected by breathalyzer test (EOT of ID-078A301 or ID-078A302 studies if same day as Visit 1 or Visit 1 if within 7 days after EOT).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total no. of Subjects With at Least One TEAE","description":"The primary objective of the study was to assess the long-term safety and tolerability of 10, 25 and 50 mg daridorexant.\n\nThe total no. of subjects with at least one TEAE is presented here; no statistical analysis was conducted.\n\nThe full set of safety data is available in the Section \"Adverse events\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"45","spread":null},{"groupId":"OG004","value":"48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":142},"commonTop":["Nasopharyngitis"]}}}